AZN

AstraZeneca PLC

66.64
USD
3.08%
66.64
USD
3.08%
53.63 71.70
52 weeks
52 weeks

Mkt Cap 206.51B

Shares Out 3.10B

Chat
Send me real-time posts from this site at my email

AstraZeneca : Enhertu Recommended For Approval In EU By CHMP For Metastatic Breast Cancer

(RTTNews) - AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo's Enhertu or trastuzumab deruxtecan has been recommended for approval in the European Union by the Committee for Medicinal Products for Human Use (CHMP) for adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. The recommendation was based on DESTINY-Breast03 trial results showing the companies' Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1). The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. Enhertu is being further assessed in a comprehensive clinical development programme evaluating efficacy and safety across multiple HER2-targetable cancers, including breast, gastric, lung and colorectal cancers. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue